If you have been diagnosed with Geographic Atrophy (GA), Opinion Research would like to speak with you at your convenience during the next two weeks. They are offering an honorarium of $150.00 in cash as a thank-you for spending sixty minutes of your time to share your opinions about treatments that might be available for [Read More]
Category: Latest News
Blindness Awareness Month on Legally Blind No Limits is presented by Prevent Blindness
Blindness Awareness Month on Legally Blind No Limits is presented by Prevent Blindness, the Living Well with Low Vision Initiative and the ASPECT Program! Looking for something fun to tune into during Blindness Awareness Month? Cory Rainford, advocate and creator behind Legally Blind No Limits, is bringing the community together every Tuesday for livestreams filled [Read More]
Opportunity for Paid Telephone Interview
IQVIA is currently looking for individuals with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) who are being treated with EYLEA HD® to take part in a 60-minute telephone interview. To thank you for your time and effort, you will be compensated $200 following completion of your interview ($150 for your time completing the [Read More]
Share Your Story About Step Therapy
The Prevent Blindness government affairs team has been notified of a potential opportunity to share your story with lawmakers about the harmful impact of “step therapy.” We understand that, in an effort to pass the Safe Step Act into law, legislators want to hear patient stories that will help compel action on this important bill. [Read More]
FDA Approves Updated Vabysmo Label To Extend Treatment For Macular Edema Following Retinal Vein Occlusion (Rvo) Beyond Six Months
Genentech has received FDA approval of Vabysmo® for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months. RVO affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease. “This label update reinforces our commitment to delivering consistent, long-term solutions for patients [Read More]